Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer
This first IPD meta-analysis evaluating RMST and RMTL as alternative endpoints in ES-SCLC demonstrates that these measures generally align with HR, with some exceptions. Given their clinical interpretability and ability to quantify survival benefit, RMST and RMTL should be considered as endpoints in future ES-SCLC trials.
Authors
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- Pingfu Fu (ORCID: https://orcid.org/0000-0002-2334-5218)
- Seren Durer (ORCID: https://orcid.org/0009-0008-5105-4689)
- Zhengyi Chen (ORCID: https://orcid.org/0000-0002-2745-4454)
Institutions
- University Hospitals Seidman Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0387
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00